Press Release

Sysmex Begins Selling Hemostasis Instruments and Reagents Under the Sysmex Brand in the United States and EU Countries

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) and Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.) (“Siemens Healthineers”) announce that from April 2024, the companies have begun to distribute independently their combined portfolio of hemostasis testing solutions to laboratories in the United States and EU countries* under the companies’ respective brands based on a mutual OEM supply initiative. This distribution is based on a global OEM agreement on hemostasis products concluded in February 2023 (hereinafter, "Agreement"). Moving forward, we will gradually expand the implementation of sales through this initiative on a global scale.

Since entering into a global agreement on distribution, sales, and services for hemostasis products in 1995, Sysmex and Siemens Healthineers have built a solid partnership for over 25 years, together becoming one of the leading solution providers in the global hemostasis segment.
In February 2023, with the aim of providing broader and more effective hemostasis laboratory solutions to customers worldwide, the companies concluded the Agreement to sell products and services, globally and individually, under their respective brands. This involves supplying each other with respective hemostasis instruments and reagents and combining such hemostasis products with their own wider portfolios of products and services. Since then, the companies have been preparing for transition, such as regulatory registrations required for the sale of OEM products. The companies have commenced independent sales of hemostasis solutions under their individual brands in the United States and EU countries* from April 2024.
This will enable Sysmex to provide even more effective solutions under our own brand by combining our strengths with the world’s leading hemostasis product portfolios. Starting with the United States and EU countries*, which have been vital areas of expansion in our hemostasis field, Sysmex will progressively extend this new initiative to other countries and regions.
Going forward, Sysmex will continue to provide solutions that will exceed customer expectations, and will remain committed to further enhancing the value of hemostasis testing to realize a better healthcare journey.
*Countries including EU member states, Iceland, Liechtenstein, and Norway

Voices from Leadership:

March 8, 2023, news release: “Sysmex and Siemens Healthineers Establish Global Agreement to Supply Hemostasis Instruments and Reagents as OEMs”

About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. 
"Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.

For more information about Sysmex, please visit


  • The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.

Back to "News"